Ebola emergency turns spotlight on experimental drugs
Published on Aug 7, 2014 1:00 PM
CHICAGO/NEW YORK (REUTERS) - With hundreds of patients in Africa suffering the devastating effects of Ebola, health experts are scrambling to determine which drugs might offer the best experimental treatment, and researchers are being pressed by government officials to speed up their work.
Three treatments have shown especially promising results in monkeys, the researchers said.
One, produced by tiny California biotech Mapp Biopharmaceutical, gained international prominence this week when it was given to two US aid workers who contracted Ebola in West Africa and have since shown signs of improvement.
Others are from Vancouver-based Tekmira Pharmaceuticals and privately-held Profectus BioSciences, of Tarrytown, NY.
To continue reading, log in if you are a subscriber
If you are not a subscriber, you can get instant, unlimited access here